PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 02/20/24

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten upsized public offering of 22,560,001 shares ...

2024-02-15 04:39:41 ET More on Prime Medicine Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing Prime Medicine stock falls on proposed public offering of common stock Prime Medicine wins up to $15M to find cure for cystic fibrosis ...

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten upsized public offering of 19,200,001 shares o...

2024-02-14 16:16:40 ET More on Prime Medicine Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing Prime Medicine wins up to $15M to find cure for cystic fibrosis Stifel cuts Prime Medicine to hold, cites quieter catalyst outlook ...

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of $125.0 million of sh...

2024-02-12 01:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime...

2024-01-28 08:11:06 ET Summary Prime Medicine is a gene editing company at the forefront of genetic therapies, with a promising pipeline and preclinical successes. The company has made substantial investments in R&D, demonstrating its commitment to innovation and belief in its...

2024-01-25 13:06:47 ET More on Prime Medicine Stifel cuts Prime Medicine to hold, cites quieter catalyst outlook Prime Medicine GAAP EPS of -$0.55 misses by $0.07 Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime Medicin...

CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the...